We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Silver ciprofloxacin (CIPAG): a multitargeted metallodrug in the development of breast cancer therapy.
- Authors
Banti, Christina N.; Kalousi, Foteini D.; Psarra, Anna-Maria G.; Moushi, Eleni E.; Leonidas, Demetres D.; Hadjikakou, Sotiris K.
- Abstract
The anti-proliferative activity of the known metalloantibiotic {[Ag(CIPH)2]NO3∙0.75MeOH∙1.2H2O} (CIPAG) (CIPH = ciprofloxacin) against the human breast adenocarcinoma cancer cells MCF-7 (hormone dependent (HD)) and MDA-MB-231 (hormone independent (HI)) is evaluated. The in vitro toxicity and genotoxicity of the metalloantibiotic were estimated toward fetal lung fibroblast (MRC-5) cells. The molecular mechanism of the CIPAG activity against MCF-7 cells was clarified by the (i) cell morphology, (ii) cell cycle arrest, (iii) mitochondrial membrane permeabilization, and (iv) by the assessment of the possible differential effect of CIPAG on estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) transcriptional activation, applying luciferase reporter gene assay. Moreover, the ex vivo mechanism of CIPAG was clarified by its binding affinity toward calf thymus (CT-DNA).
- Subjects
BREAST cancer; CIPROFLOXACIN; BREAST; CARCINOGENESIS; CANCER treatment; CELL morphology
- Publication
Journal of Biological Inorganic Chemistry (JBIC), 2024, Vol 29, Issue 2, p177
- ISSN
0949-8257
- Publication type
Article
- DOI
10.1007/s00775-024-02048-y